InsidersTradesSigma
Adial Pharmaceuticals, INC. Stock: price and management transactions · United States · SEC (Form 4)
Follow the Adial Pharmaceuticals, INC. share price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are quoted on US US, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Adial Pharmaceuticals, INC. has published 25 insider filings. Market capitalisation: €6.3m. The latest transaction was disclosed on 1 July 2026 (Acquisition). Among the most active insiders: Davidson Matt. Every trade is openly available.
25
Insider Decl.
0
Thresholds
€145,350
8 ops.
Buy Volume
·
3 ops.
Sell Volume
59Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 1 July 2026
Declarations25 total
25,000 sharesCommon StockSEC:0001104659-26-079686:0
Ideal exit: 26 Mar 2027 (T+270)
61,647 sharesCommon StockSEC:0001213900-26-069037:0
3,427 sharesCommon StockSEC:0001213900-26-069037:1
232,417 sharesCommon StockSEC:0001213900-26-069037:2
1,822.13 sharesSeries A Preferred StockSEC:0001213900-26-069037:3
101.298 sharesSeries A Preferred StockSEC:0001213900-26-069037:4
700 shares@ US$2.74100.0% of flowCommon StockSEC:0001013762-23-000757:0
Ideal exit: 25 Jun 2024 (T+270)
420,000 shares0Common StockSEC:0001213900-23-043111:0
240,800 shares0Common StockSEC:0001213900-23-043129:0
157,500 shares0Common StockSEC:0001213900-23-043133:0
166,667 shares0Common StockSEC:0001213900-23-000003:0
25,000 shares@ US$0.429425.3% of flowCommon StockSEC:0001213900-22-057513:0
75,000 shares@ US$0.420274.7% of flowCommon StockSEC:0001213900-22-057513:1
1,000,000 shares0Common StockSEC:0001213900-22-050082:0
250,000 shares0Common StockSEC:0001213900-22-009432:0
10,000 shares@ US$2.6624.0% of flowCommon StockSEC:0001213900-22-000067
Ideal exit: 26 Sept 2022 (T+270)
10,000 shares@ US$2.660.79% mcap24.0% of flowCommon StockSEC:0001213900-22-000067:0
Ideal exit: 26 Sept 2022 (T+270)
312,990 shares0Common StockSEC:0001213900-21-067352
312,990 shares0Common StockSEC:0001213900-21-067352:0
10,000 shares@ US$2.58920.78% mcap50.0% of flowCommon StockSEC:0001213900-21-062729:0
Ideal exit: 26 Aug 2022 (T+270)
10,000 shares@ US$2.589250.0% of flowCommon StockSEC:0001213900-21-062729
Ideal exit: 26 Aug 2022 (T+270)
10,000 shares@ US$2.8526.0% of flowCommon StockSEC:0001213900-21-062465
Ideal exit: 23 Aug 2022 (T+270)
10,000 shares@ US$2.850.86% mcap26.0% of flowCommon StockSEC:0001213900-21-062465:0
Ideal exit: 23 Aug 2022 (T+270)
200,000 sharesCommon StockSEC:0001213900-21-051646:0
200,000 sharesCommon StockSEC:0001213900-21-051646
25 of 25 declarations
About Adial Pharmaceuticals, INC.
Adial Pharmaceuticals, Inc. is a U.S.-based biopharmaceutical company listed on the NASDAQ under the ticker ADIL in the United States. For French-speaking investors, it is best viewed as a development-stage healthcare name rather than a commercial-stage drug company. The business is headquartered in Glen Allen, Virginia, and its roots go back to ADial Pharmaceuticals, L.L.C., which was formed in November 2010 before later becoming a public corporation. Over time, Adial has built a focused clinical pipeline around addiction and related disorders. The company’s core activity is the development of therapies for the treatment and prevention of alcohol use disorder and other addiction-related conditions. Its lead investigational asset is AD04, a serotonin-3 receptor antagonist being studied for Alcohol Use Disorder (AUD). Adial has positioned AD04 within a precision-medicine framework, emphasizing biomarker-based patient selection and a potentially differentiated approach to treatment. That matters strategically because the addiction-treatment market remains medically underserved, and successful drug development in this area could address a meaningful unmet need. From a competitive standpoint, Adial sits in the small-cap biotech segment, where valuation is driven primarily by clinical milestones, regulatory progress, and access to capital. Its potential strengths include a narrow therapeutic focus and a lead asset aimed at a large and persistent public-health problem. However, the company also faces the usual biotech constraints: competition from larger pharmaceutical groups, uncertainty around clinical outcomes, and the need to secure financing before any meaningful product revenue can materialize. Until a product is approved and commercialized, Adial remains a high-risk, binary-outcome investment profile. Geographically, the company’s operations are primarily U.S.-centered, and its corporate and regulatory footprint is firmly based in the United States. Recent company updates indicate that Adial has been advancing its FDA dialogue and preparing for a planned Phase 3 program for AD04, while also discussing potential partnering opportunities. A notable recent development came in February 2026, when the company announced that it had regained compliance with Nasdaq’s minimum bid-price requirement after earlier pressure on the share price and a reverse stock split. That episode underscores the company’s financing sensitivity and market volatility. Overall, Adial Pharmaceuticals is a specialized NASDAQ-listed U.S. biotech company with a single lead program, a clear focus on addiction medicine, and a risk-return profile typical of clinical-stage pharmaceutical developers: significant upside tied to regulatory and clinical success, but substantial execution, funding, and dilution risk along the way.
